These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 8456595)
1. Treatment of cognitive impairment secondary to degenerative dementia. Effectiveness of oxiracetam therapy. Rozzini R; Zanetti O; Bianchetti A Acta Neurol (Napoli); 1993 Feb; 15(1):44-52. PubMed ID: 8456595 [TBL] [Abstract][Full Text] [Related]
2. Effectiveness of oxiracetam therapy in the treatment of cognitive deficiencies secondary to primary degenerative dementia. Rozzini R; Zanetti O; Bianchetti A Acta Neurol (Napoli); 1992 Apr; 14(2):117-26. PubMed ID: 1414555 [TBL] [Abstract][Full Text] [Related]
3. Activity of oxiracetam in patients with organic brain syndrome: a neuropsychological study. Moglia A; Sinforiani E; Zandrini C; Gualtieri S; Corsico R; Arrigo A Clin Neuropharmacol; 1986; 9 Suppl 3():S73-8. PubMed ID: 3594459 [TBL] [Abstract][Full Text] [Related]
4. Clinical and neuropsychological study with oxiracetam versus placebo in patients with mild to moderate dementia. Villardita C; Parini J; Grioli S; Quattropani M; Lomeo C; Scapagnini U J Neural Transm Suppl; 1987; 24():293-8. PubMed ID: 3479527 [TBL] [Abstract][Full Text] [Related]
5. Benefits of rivastigmine on attention in dementia associated with Parkinson disease. Wesnes KA; McKeith I; Edgar C; Emre M; Lane R Neurology; 2005 Nov; 65(10):1654-6. PubMed ID: 16301500 [TBL] [Abstract][Full Text] [Related]
6. Clinical studies with oxiracetam in patients with dementia of Alzheimer type and multi-infarct dementia of mild to moderate degree. Villardita C; Grioli S; Lomeo C; Cattaneo C; Parini J Neuropsychobiology; 1992; 25(1):24-8. PubMed ID: 1603291 [TBL] [Abstract][Full Text] [Related]
7. A clinical and neurophysiological trial on nootropic drugs in patients with mental decline. Gallai V; Mazzotta G; Del Gatto F; Montesi S; Mazzetti A; Dominici P; Della Monica A Acta Neurol (Napoli); 1991 Feb; 13(1):1-12. PubMed ID: 1867125 [TBL] [Abstract][Full Text] [Related]
8. [Cognitive enhancement effect of piracetam in patients with mild cognitive impairment and dementia]. Tariska P; Paksy A Orv Hetil; 2000 May; 141(22):1189-93. PubMed ID: 10853348 [TBL] [Abstract][Full Text] [Related]
9. Influence of major antiepileptic drugs on attention, reaction time, and speed of information processing: results from a randomized, double-blind, placebo-controlled withdrawal study of seizure-free epilepsy patients receiving monotherapy. Hessen E; Lossius MI; Reinvang I; Gjerstad L Epilepsia; 2006 Dec; 47(12):2038-45. PubMed ID: 17201701 [TBL] [Abstract][Full Text] [Related]
10. Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial. Doody RS; Ferris SH; Salloway S; Sun Y; Goldman R; Watkins WE; Xu Y; Murthy AK Neurology; 2009 May; 72(18):1555-61. PubMed ID: 19176895 [TBL] [Abstract][Full Text] [Related]
13. Oxiracetam in the treatment of multi-infarct dementia and primary degenerative dementia. Dysken MW; Katz R; Stallone F; Kuskowski M J Neuropsychiatry Clin Neurosci; 1989; 1(3):249-52. PubMed ID: 2521069 [TBL] [Abstract][Full Text] [Related]
14. Selegiline versus oxiracetam in patients with Alzheimer-type dementia. Falsaperla A; Monici Preti PA; Oliani C Clin Ther; 1990; 12(5):376-84. PubMed ID: 2125242 [TBL] [Abstract][Full Text] [Related]
15. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)]. Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451 [TBL] [Abstract][Full Text] [Related]